Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01237-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Ruyi Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Fourth Affiliated Hospital (Affiliated Chaohu Hospital) of Anhui Medical University), Chaohu, Anhui, People's …. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, Klebsiella Infections, Tetracyclines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Natural Science Research Project of Anhui Province.
Abstract (Originalsprache)
Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) presents a major challenge for clinical treatment due to its characteristics of drug resistance and hypervirulence. This study aims to investigate the therapeutic effect of a novel tetracycline antibiotic, eravacycline, on CR-hvKP pneumonia. We isolated three CR-hvKP strains from clinical samples and examined their associated phenotypes. Subsequently, we infected mice with strains. The results indicated that the clinical isolates KP78, KP98, and KP100 carried multiple drug resistance genes and virulence genes, exhibiting high virulence levels and significantly resistant to neutrophil-mediated intracellular killing ( P < 0.01). The body weight of infected mice decreased significantly ( P < 0.0001). At the same time, the bacteria entered the blood from the lungs and spread to other organs. After the administration of eravacycline, the body weight of the mice began to increase 36 h later. The number of bacterial colonizing in the lungs was reduced ( P < 0.01), the infiltration of inflammatory cells was reduced, and the interstitial vascular dilatation and congestion were alleviated. Meanwhile, eravacycline significantly suppressed the serum levels of cytokines IL-6, IL-1β, and MCP-1 ( P < 0.05). Notably, eravacycline suppressed the mRNA expression of STAT1 and p-STAT1 activation in the lung tissue of mice in the treatment group. In conclusion, clinical isolates KP78, KP98, and KP100 caused severe lung injury after invading mouse lung tissues, and eravacycline attenuated the lung injury and inflammatory response induced by CR-hvKP invasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The Fourth Affiliated Hospital (Affiliated Chaohu Hospital) of Anhui Medical University), Chaohu, Anhui, People's Republic of China.
- Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
ORCID-Profile: Ruyi Zhang, Wei Xu, Mei Zhu
Förderung
- University Natural Science Research Project of Anhui Province
Zitieren
APA
Zhang, R., Zhang, C., Liu, J., Kong, X., Zhang, S., Chang, M., Xu, W., & Zhu, M. (2026). Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01237-25
Vancouver
Zhang R, Zhang C, Liu J, Kong X, Zhang S, Chang M, et al. Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01237-25
BibTeX
@article{Zhang2026,
author = {Zhang, Ruyi and Zhang, Chenchen and Liu, Juan and Kong, Xiaoli and Zhang, Shulei and Chang, Miaosu and Xu, Wei and Zhu, Mei},
title = {Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01237-25}
}
EUVIMED